Prot #CAB-201-002: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy

Project: Research project

Project Details

StatusActive
Effective start/end date7/10/24 → 7/10/27

Funding

  • Advanced Clinical LLC (Prot #CAB-201-002 // Prot #CAB-201-002)
  • Cabaletta Bio, Inc. (Prot #CAB-201-002 // Prot #CAB-201-002)